What are Enliven Therapeutics's total assets?

Enliven Therapeutics (ELVN) holds $464.9M in total assets, up 53.6% year over year.

How much debt does Enliven Therapeutics have?

Enliven Therapeutics carries $302.0K in total debt against $453.4M of shareholders' equity, a debt-to-equity ratio of 0.00.

How much cash does Enliven Therapeutics have?

Enliven Therapeutics holds $132.2M in cash and equivalents.

Can Enliven Therapeutics cover its short-term obligations?

Its current ratio is 40.32 — current assets exceed current liabilities.

Where does Enliven Therapeutics's balance sheet data come from?

Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Enliven Therapeutics ELVN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Cash and cash equivalents	$132.18M+30.0%	$98.9M-20.3%	$101.73M+1.1%	$119.44M+23.3%	$101.71M-31.8%
Short-term investments	$320.22M+70.5%	$363.73M+92.1%	$375.83M+96.6%	$371.07M+72.2%	$187.85M+9.6%
Prepaid expenses and other current assets	$10.74M+125%	$12.26M+165%	$5.12M+0.2%	$5.12M-9.9%	$4.76M-28.3%
Total current assets	$463.14M+57.4%	$474.88M+49.3%	$482.68M+62.5%	$495.62M+55.8%	$294.32M-12.7%
Property and equipment, net	$20K-95.0%	$34K-92.6%	$399K-27.3%	$462K-26.7%	$404K-40.8%
Operating lease right-of-use assets	$290K-58.6%	$383K—	$475K+486%	$564K+250%	$700K+190%
Other non-current assets	$1.19M-83.5%	$656K-90.9%	$7.1M-1.9%	$7.24M-4.3%	$7.2M+75.9%
Total assets	$464.85M+53.6%	$476.17M+46.2%	$490.88M+60.7%	$503.89M+54.1%	$302.57M-11.7%
Accounts payable	$1.64M+5.0%	$2.16M+60.9%	$1.43M+40.2%	$2.35M+117%	$1.56M-42.7%
Operating lease liabilities, current	$302K-17.3%	$399K—	$387K+355%	$376K+122%	$365K+44.8%
Total current liabilities	$11.49M-17.8%	$16.57M+4.1%	$14.65M-14.0%	$15.21M-31.2%	$13.97M-44.2%
Operating Lease Liabilities (Total)	$302K-56.9%	$399K—	$490K+476%	$580K+243%	$700K+178%
Total liabilities	$11.49M-19.5%	$16.57M+4.1%	$14.75M-13.4%	$15.42M-30.3%	$14.27M-43.1%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	$61K+24.5%	$59K+20.4%	$59K+25.5%	$59K+25.5%	$49K+4.3%
Additional paid-in capital	$824.48M+47.2%	$806.37M+45.8%	$793.34M+56.0%	$785.94M+56.5%	$560.28M+13.2%
Retained earnings	-$370.79M-36.3%	-$347.17M-42.6%	-$317.5M-44.1%	-$297.35M-50.8%	-$272.02M-53.5%
Accumulated other comprehensive income (loss)	-$382K-2,288%	$334K+507%	$221K-8.7%	-$177K-27.3%	-$16K+69.8%
Total stockholders' equity	$453.37M+57.3%	$459.6M+48.3%	$476.12M+65.1%	$488.47M+60.2%	$288.3M-9.3%
Total liabilities and stockholders' equity	$464.85M+53.6%	$476.17M+46.2%	$490.88M+60.7%	$503.89M+54.1%	$302.57M-11.7%
Short- term Investments	$320.22M+70.5%	$363.73M+92.1%	$375.83M+96.6%	$371.07M+72.2%	$187.85M+9.6%
Deferred Tax Assets and Other Non-Current Assets	$1.19M-83.5%	$656K-90.9%	$7.1M-1.9%	$7.24M-4.3%	$7.2M+75.9%
Net Investment in Lease	$290K-58.6%	$383K—	$475K+486%	$564K+250%	$700K+190%
Deferred Offering Costs Non Current	$217K—	$217K—	$217K-61.5%	——	——
Operating lease right-of-use assets	$290K-58.6%	$383K—	$475K+486%	$564K+250%	$700K+190%
Other non-current assets	$1.19M-83.5%	$656K-90.9%	$7.1M-1.9%	$7.24M-4.3%	$7.2M+75.9%
Operating Lease Right-of-Use Assets in Other Assets	$290K-58.6%	$383K—	$475K+486%	$564K+250%	$700K+190%
Software and Technology Licenses, Net	$1.19M-83.5%	$656K-90.9%	$7.1M-1.9%	$7.24M-4.3%	$7.2M+75.9%
Accrued Expenses And Other Current Liabilities	$9.85M-20.7%	$14.41M-1.1%	$13.22M-17.4%	$12.86M+8.8%	$12.41M+0.9%
Total debt	$302K-56.9%	$399K—	$490K+476%	$580K+243%	$700K+178%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$61K+24.5%	$59K+20.4%	$59K+25.5%	$59K+25.5%	$49K+4.3%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Enliven Therapeutics's total assets?: Enliven Therapeutics (ELVN) holds $464.9M in total assets, up 53.6% year over year.
How much debt does Enliven Therapeutics have?: Enliven Therapeutics carries $302.0K in total debt against $453.4M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Enliven Therapeutics have?: Enliven Therapeutics holds $132.2M in cash and equivalents.
Can Enliven Therapeutics cover its short-term obligations?: Its current ratio is 40.32 — current assets exceed current liabilities.
Where does Enliven Therapeutics's balance sheet data come from?: Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.